**Author details**

Siyang Chaili and Sean D. Adrean\* Retina Consultants of Orange County, Fullerton, CA, USA

\*Address all correspondence to: seadrean@yahoo.com

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**219**

*Management Strategies and Visual Results for the Treatment of Neovascular Age-Related…*

age-related macular degeneration with photodynamic therapy (TAP) Study Group. Archives of Ophthalmology.

[10] Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization– verteporfin in photodynamic therapy

report 2. American Journal of Ophthalmology. 2001;**131**(5):541-560

and Technology. 2016;**5**(2):9

[11] Miller JW. VEGF: From discovery to therapy: The Champalimaud award lecture. Translational Vision Science

[12] VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;**113**(9):1508.e1-1508.25

[13] Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an

Surgery, Lasers & Imaging.

2005;**36**(4):331-335

2006;**355**:1419-1431

intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic

[14] Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. NEJM.

[15] Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;**116**(1):57-65.e5

1999;**117**(10):1329-1345

*DOI: http://dx.doi.org/10.5772/intechopen.81466*

[1] Age-Related Macular Degeneration (AMD) [Internet]. 2018. Available from: https://nei.nih.gov/eyedata/amd

[2] Causes of blindness and visual impairment. [Internet]. 2018. Available from: http://www.who.int/blindness/ causes/en/ [Accessed: 01 July 2018]

[3] Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy:

[4] Hm L, Krueger DE, Maunder LR, et al. The Framingham eye study monograph. Survey of Ophthalmology.

[5] Coleman HR, Chan CC, Ferris FL

[6] Jager RD, Mieler WF, Miller JW. Agerelated macular degeneration. The New England Journal of Medicine.

[7] Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Archives of Ophthalmology.

[8] Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Archives of Ophthalmology.

[9] TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials–TAP report. Treatment of

The beaver dam eye study. Ophthalmology. 1991;**99**:933-943

III, Chew EY. Age-related macular degeneration. Lancet. 2008;**372**(9652):1835-1845

2008;**358**(24):2606-2617

1991;**109**(8):1109-1114

1990;**108**(6):816-824

1980;**24**:335-610

**References**

[Accessed: 01 July 2018]

*Management Strategies and Visual Results for the Treatment of Neovascular Age-Related… DOI: http://dx.doi.org/10.5772/intechopen.81466*
